en · de · es · fr · pt
tesamorelin-notes.peptides8425.com › Guide › Tesamorelin �ƒŒ景与作用机制 — Research Overview

Tesamorelin �ƒŒ景与作用机制 — Research Overview

By Editorial Desk · published 2026-06-22 · last reviewed 2026-07-25 · Guide

The short version of GHRH 类似物 fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-07-25. Anything still debated is marked as such rather than presented as settled.

tesamorelin 背景与作用机制

作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶,升高细胞内 cAMP,再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点,生长激素仍以脉冲方式分泌,而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生,构成完整的生长激素轴响应。

研究背景集中在特定人群的体成分改变,尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致,部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题,现有数据不足以给出普遍结论。

tesamorelin 是一种人工合成的四十四肽,序列与内源性生长激素释放激素(GHRH)的 1-44 片段一致,区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割,从而延长分子在循环中的存留时间。作为肽类分子,它难以经胃肠道吸收,文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物,以区别于生长激素本身。

Background and Clinical Profile

Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.

Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.

After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.

Tesamorelin at a glance

性质取值备注
分子类型合成四十四肽GHRH 类似物
N 端修饰反式-3-己烯酰基延缓酶切
分子量约 5135 Da依序列与修饰
受体靶点垂体 GHRH 受体经 cAMP 通路
常见同义名GHRH(1-44) 类似物文献通用称法

Background and Clinical Development

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Related pages on this site

Notes from published material

=== Pancreatic cancer cells === This type of collagen can cause an increase in pancreatic cancer cells and is able to inhibit apoptosis through an autocrine loop. This autocrine loop provides essential cell survival signals to the pancreatic cancer cells. Type IV collagen is expressed close to the cancer cells in vivo, forming basement membrane like structures on the cancer cell surface that colocalize with the integrin receptors. The interaction between type IV collagen produced by the cancer cell, and integrins on the surface of the cancer cells, are important for continuous cancer cell growth, maintenance of a migratory phenotype, and for avoiding apoptosis.

Calcium (20Ca) has 26 known isotopes, ranging from 35Ca to 60Ca. There are five stable isotopes (40Ca, 42Ca, 43Ca, 44Ca and 46Ca), plus one isotope (48Ca) with such a long half-life that it is for all practical purposes stable. Two isotopes of calcium, 40Ca and 48Ca, are doubly-magic, making them particularly stable nucliides. Calcium also has a cosmogenic isotope, 41Ca, with half-life 99,400 years. Unlike cosmogenic isotopes produced in the air, 41Ca is produced by neutron activation of solid 40Ca in rock and soil. Most of its production is in the upper meter of the soil column, where the cosmogenic neutron flux is still strong enough. Calcium-41 is also produced during stellar nucleosynthesis and decays to 41K, which can be used to understand formation and mixing between solar system reservoirs . The most stable artificial isotopes are 45Ca with half-life 162.61 days and 47Ca with half-life 4.536 days. All other artificial calcium isotopes have half-lives of minutes or less. 40Ca comprises about 97% of natural calcium and is mainly created by nucleosynthesis in stars (alpha process). Like 40Ar, however, some 40Ca is radiogenic, created by radioactive decay of 40K. While K–Ar dating has been used extensively in the geological sciences, the prevalence of 40Ca in nature initially impeded the proliferation of K-Ca dating in early studies, with only a handful of studies in the 20th century.

With the expiration of many patents for blockbuster biologics between 2012 and 2019, the interest in biosimilar production, i.e., follow-on biologics, has increased. Compared to small molecules that consist of chemically identical active ingredients, biologics are vastly more complex and consist of a multitude of subspecies. Due to their heterogeneity and the high process sensitivity, originators and follow-on biosimilars will exhibit variability in specific variants over time. The safety and clinical performance of both originator and biosimilar biopharmaceuticals must remain equivalent throughout their lifecycle. Process variations are monitored by modern analytical tools (e.g., liquid chromatography, immunoassays, mass spectrometry, etc.) and describe a unique design space for each biologic. Biosimilars require a different regulatory framework compared to small-molecule generics. Legislation in the 21st century has addressed this by recognizing an intermediate ground of testing for biosimilars. The filing pathway requires more testing than for small-molecule generics, but less testing than for registering completely new therapeutics. In 2003, the European Medicines Agency introduced an adapted pathway for biosimilars, termed similar biological medicinal products. This pathway is based on a thorough demonstration of comparability of the product to an existing approved product.

=== Beginnings === As of 1969, the Escadrille Nationale Tchadienne was equipped with five Douglas C-47 cargo aircraft and three Max Holste MH.1521 Broussard liaison aircraft. Most of them were operated by French crews, because there were very few native pilots. In the mid-1970s, it was reinforced by six AD-4N Skyraiders, as well as some additional C-47 and Douglas C-54 transports, the total number of which reached 13 by that time. All of these were donated by France, and most were still crewed by the French. Three Reims-Cessna FTB337s were also delivered in 1977.

The antagonist has a peptide moiety. The nomenclature of the somatostatin receptor antagonists is also based on this order. The structure of somatostatin receptor antagonists are similar to that of the agonists. Some agonists were already approved by the FDA for clinical use, such as In-DTPA-octreotide and Ga-DOTATATE. Development started after the discovery of modifications that can be done to the octreotide group, a ssrt selective subtype agonist, to cause its agonistic effects to be lost and gain antagonistic effects. Different subtype receptor antagonists were later developed. Research has mostly been done on the sstr2 receptor antagonist, as the sstr2 receptor is expressed on most tumors. Somatostatin receptor antagonists are divided by generation based on the type of the subtype receptor antagonist. The first generation consists of sst2-ANT and BASS, which are sstr2 selective; and sst3-ODAN-8, which is selective for sstr3. After initial results of their increased sensitivity to neurocrine tumors appeared, ssrt2 selective antagonists that had even higher affinity were developed. These were LM3, JR10, and JR11, which make up the second generation. JR11 was shown to be the most effective among these 3 antagonists, and compounds that entered further clinical development to act as a PET imaging agent or therapeutic agent carried this subtype antagonist. The presence of a chelator coupled to the subtype antagonist was shown to have an effect on the biologic properties. Compounds were developed with 3 macrocyclic chelators: DOTA, NODAGA, and CB-TE2A.

Sources: en.wikipedia.org

Background from the literature

=== May === 1 May – The EU–Mercosur Partnership Agreement comes into effect. 14 May – After 68 years on the air, Eldorado FM radio is ceasing operations in São Paulo. 5 May – Two people are killed in a school shooting in Rio Branco, Acre. 28 May – The United States designates the Primeiro Comando da Capital and the Comando Vermelho as terrorist organizations.

=== Cancers === Lung cancer can either arise directly from lung tissue or as a result of metastasis from another part of the body. There are two main types of primary tumour described as either small-cell or non-small-cell lung carcinomas. The major risk factor for cancer is smoking. Once a cancer is identified it is staged using scans such as a CT scan and a sample of tissue from a biopsy is taken. Cancers may be treated surgically by removing the tumour, the use of radiotherapy, chemotherapy or a combination, or with the aim of symptom control. Lung cancer screening is being recommended in the United States for high-risk populations.

== Structure == The crystal structure of AGAT was determined by Humm, Fritsche, Steinbacher, and Huber of the Max Planck Institute of Biochemistry in Martinsried, Germany in 1997. X-ray examinations of the structure reveal a novel symmetry with fivefold pseudosymmetry of beta beta alphabeta modules. The overall structure of the molecule resembles a basket with handles. The active site lies at the bottom of a long, narrow channel and includes a Cys-His-Asp catalytic triad. The intermediate structure involves the amidino group temporarily covalently bonding to the Cys residue on the catalytic triad, while the His residue takes part in general acid/base catalysis, meaning it acts as a proton donator/receiver itself.

== Medical uses == Hydroxychloroquine treats rheumatic disorders such as systemic lupus erythematosus, rheumatoid arthritis, and porphyria cutanea tarda, and certain infections such as Q fever and certain types of malaria. It is considered the first-line treatment for systemic lupus erythematosus. Certain types of malaria, resistant strains, and complicated cases require different or additional medication. Hydroxychloroquine blocks the effects of some chemicals released in autoimmune diseases, and is used to treat inflammatory conditions. It is widely used to treat primary Sjögren syndrome but does not appear to be effective. Hydroxychloroquine is widely used in the treatment of post-Lyme arthritis. It may have both an anti-spirochete activity and an anti-inflammatory activity, similar to the treatment of rheumatoid arthritis.

Sources: en.wikipedia.org

Frequently asked questions

tesamorelin 与生长激素有什么区别?

tesamorelin 属 GHRH 类似物,作用于垂体受体以促进内源生长激素释放;生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。

它通常以何种方式进入体内?

作为多肽,它难以通过胃肠道吸收,通常需要注射给药。口服会因消化酶降解而失去活性,因此文献中讨论的都是注射途径。

目前研究主要关注哪些方向?

公开研究多集中在内脏脂肪、体成分分布以及与生长激素轴相关的代谢指标。长期安全性和在普通人群中的适用性尚缺乏一致结论。

What is tesamorelin?

It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.

Network